Hudson Therapeutics, Inc. Press Releases - EIN Presswire

Published on March 17, 2025 - 13:04 GMT

Hudson Therapeutics to Conduct Global Licensing Discussions for NuGel at Bio Europe Spring 2025

Next-Generation Atopic Dermatitis Treatment Moves Forward with Global Development and Licensing Opportunities DURHAM, NC, UNITED STATES, March 17, 2025 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on March 5, 2025 - 12:40 GMT

Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for Nugel

Next-Generation Atopic Dermatitis Treatment Moves Forward with Global Development and Licensing Opportunities DURHAM, NC, UNITED STATES, March 5, 2025 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 24, 2025 - 12:37 GMT

Hudson Therapeutics and Shaperon Report Positive Result of Phase 2B Part 1 for Nugel at JPM 2025

DURHAM, NC, UNITED STATES, January 24, 2025 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics and Shaperon announced on January 24th that they engaged in in-depth discussions about out-licensing their next-generation atopic dermatitis treatment, NuGel, with …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 16, 2025 - 19:32 GMT

Hudson Therapeutics Announces Completion of Phase 2b Part 1 Clinical Trial for Nugel

SAN FRANCISCO, CA, UNITED STATES, January 16, 2025 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced the successful completion of Part 1 of the U.S. Phase 2b clinical trial for Nugel, the world’s first inflammatory …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on December 9, 2024 - 12:00 GMT

Hudson Therapeutics and Shaperon to Participate in Leading Major Global Biotech Conferences at the JPM Healthcare Week

DURHAM, NC, UNITED STATES, December 9, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, the US subsidiary of Shaperon, a leading innovator in therapeutic solutions, is excited to announce its participation in three major bio industry events during Bio …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 18, 2024 - 12:00 GMT

Hudson Therapeutics and Shaperon Explore Licensing Opportunities for Oral Atopic Dermatitis Treatment for Pets

A Step into Pet Medical Market DURHAM, NC, UNITED STATES, November 18, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, a U.S. subsidiary of Shaperon, announced that together with Shaperon, it is in active discussions with top-tier global companies for …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2024 - 12:00 GMT

Hudson Therapeutics and Shaperon Engage Major Global Pharmaceutical Companies at BIO-Europe 2024

Discuss Out-Licensing Assets for Atopic Dermatitis Treatment and Other Key Assets For Other Therapeutic Indications DURHAM, NC, UNITED STATES, November 12, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, in collaboration with Shaperon, announced their …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 28, 2024 - 11:00 GMT

Shaperon Wins ‘2024 Korea CEO Hall of Fame’ Award for Third Consecutive Year

DURHAM, NC, UNITED STATES, October 28, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics is pleased to announce that Shaperon, a leader in immunotherapy innovation, has been awarded the prestigious 2024 Korea CEO Hall of Fame award in the Research and …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...

Published on October 7, 2024 - 22:00 GMT

Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4

RESEARCH TRIANGLE PARK, NC, UNITED STATES, October 7, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 26, 2024 - 11:00 GMT

Hudson Therapeutics Announces Shaperon’s Entry $9.58 billion Global Alopecia Areata Treatment Market

Shaperon Introduces Alopecia Areata Drug Candidate. RESEARCH TRIANGLE PARK, NC, UNITED STATES, September 26, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 3, 2024 - 23:00 GMT

Hudson Therapeutics 将于2024年9月参与ChinaBio®合作论坛，寻求战略合作伙伴和机构投资者

DURHAM, NORTH CAROLINA, UNITED STATES, September 4, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics 公司宣布将参加 2024 年中国生物伙伴论坛。Hudson Therapeutics 是 Shaperon 公司在美国的子公司主要致力于治疗方案的创新。此次论坛将于 9 月 10 日至 11 日在中国上海举行，汇集了全球行业领导者、投资者和生物技术及制药领域的创新者。在此次会议上，Hudson …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on September 3, 2024 - 23:00 GMT

Hudson Therapeutics Seeks Strategic Partners and Institutional Investors at ChinaBio® Partnering Forum September 2024

DURHAM, NORTH CAROLINA, USA, September 3, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics, Incorporated a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, Incorporated is pleased to announce its participation in the upcoming Bio …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on July 22, 2024 - 11:00 GMT

Shaperon Publishes Efficacy of Next-Generation Cancer Immunotherapy in International Journal

Published in an international journal, the next-generation cancer immunotherapy shows 91.2% tumor growth inhibition and 97% metastasis prevention RESEARCH TRIANGLE PARK, NC, UNITED STATES, July 22, 2024 /⁨EINPresswire.com⁩/ -- Hudson Therapeutics …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...